Boehringer Ingelheim USA Corporation

Researchers from the University of Dundee and Boehringer Ingelheim developed ACBI3, a small-molecule drug that degrades KRAS mutants, showing efficacy against 13 of 17 common KRAS mutant-driven cancers. ACBI3, based on PROTACs, differs from traditional inhibitors by targeting multiple mutations and inducing tumor regression in preclinical models. Boehringer Ingelheim made ACBI3 available to the research community via its opnMe® portal to accelerate cancer research.

Boehringer Ingelheim and Insilico Medicine reported positive data from their idiopathic pulmonary fibrosis (IPF) drug trials, indicating potential to stop or reverse lung function decline. Boehringer's nerandomilast showed significant FVC improvement in a Phase III trial, while Insilico's ISM001-055 demonstrated dose-dependent FVC improvement in a Phase IIa trial. Both companies await further data and regulatory feedback.

New entrants challenge Novo Nordisk and Eli Lilly in the $200 billion GLP-1 market, with 68% of sales from weight loss by 2031. Novo and Lilly expected to retain 70% of the market but are viewed as overvalued. Next-gen obesity drugs from Roche, Amgen, Pfizer, AstraZeneca, Boehringer, and others will disrupt the market, pressuring pricing. Novo and Lilly's next-gen pipelines also advancing. Public and private firms accelerating obesity drug development through acquisitions and innovative startups.

S.K., D.A.M., J.P., H.S., X.Z., P.H., T.X., and H.S. have financial ties to various pharmaceutical companies, including stock ownership and advisory roles. F.C., J.D., E.V.C., H.S.W., T.Y., R.Y., and J.T. also report consulting or advisory roles and research funding from multiple institutions and companies.

Researchers from the University of Dundee and Boehringer Ingelheim developed ACBI3, a small-molecule drug that can degrade 13 out of 17 common KRAS mutants, offering a novel therapeutic approach for KRAS-driven cancers. ACBI3, based on PROTACs, induces tumor regression in mouse models and will be made available to the scientific community via Boehringer Ingelheim's opnMe portal.

ACBI3, a PRoteolysis TArgeting Chimera (PROTAC) developed by Professor Alessio Ciulli and Boehringer Ingelheim, rapidly eliminates 13 of the 17 most common KRAS mutants, more effectively than small molecule inhibition, inducing tumour regression in mouse models. Boehringer Ingelheim plans to make ACBI3 available through its opnMe® portal to catalyse research on KRAS degradation.

Bristol Myers Squibb awaits FDA decision on KarXT, a novel schizophrenia treatment potentially representing the first new approach in decades. KarXT, acquired via $14 billion deal with Karuna Therapeutics, targets M1 and M4 muscarinic receptors, offering efficacy without antipsychotic side effects. Other companies, including Neurocrine Biosciences, AbbVie, Reviva Pharmaceuticals, Boehringer Ingelheim, and Alto Neuroscience, are also developing schizophrenia treatments, focusing on various mechanisms to address positive, negative, and cognitive symptoms.

Insilico Medicine's AI-designed drug ISM001-055 shows positive Phase 2a results for idiopathic pulmonary fibrosis (IPF), with dose-dependent improvement in forced vital capacity (FVC). The drug targets TNIK enzyme, identified via generative AI, and is set for further Phase 2b studies. Competitors include Boehringer Ingelheim's nerandomilast and Pliant Therapeutics' bexotegrast, both showing promising results in IPF treatment.

DPHARM 2024 panel discussed adapting pharma operating models for efficient clinical trials, emphasizing the need to address scientific, technological, and regulatory complexities. Medicare's drug price negotiations may lower physician reimbursement. California's new 'deepfake' laws aim to regulate AI-generated content in elections. Deloitte found 50% of US women skip or delay medical care due to cost, access, or negative experiences, impacting long-term health and wealth. Parexel's poll revealed nearly 40% see the need for more agile service models in clinical trials, aligning with the rise of Functional Service Provider (FSP) models.

Insilico Medicine's lead candidate drug, INS018_055/ISM001-055, met safety and efficacy endpoints in a phase 2a trial for idiopathic pulmonary fibrosis (IPF), with highest dose showing significant improvement in lung function. The company plans a phase 2b trial and will release full data at a medical conference. Insilico specializes in AI-driven drug discovery, with this being the first AI-designed drug to enter phase 2 trials.